Last updated: November 4, 2026
FLULAVAL QUADRIVALENT is GSK’s egg-based, inactivated influenza vaccine for individuals aged six months and older. Its commercial performance depends on annual vaccination demand, strain composition, government procurement, manufacturing capacity, and competition from Sanofi’s Fluzone, CSL Seqirus’ Afluria and Fluad, and newer cell-based and recombinant vaccines.
GSK does not report FLULAVAL or FLULAVAL QUADRIVALENT revenue as standalone products. Financial performance must be assessed through GSK’s broader vaccines segment and influenza-vaccine disclosures. The product has no conventional small-molecule Orange Book exclusivity profile. Competitive protection is driven more by regulatory licensure, manufacturing know-how, seasonal strain updates, supply contracts, and production scale than by a single blocking patent.
What are FLULAVAL and FLULAVAL QUADRIVALENT?
FLULAVAL is an inactivated influenza vaccine manufactured using embryonated chicken eggs. FLULAVAL QUADRIVALENT contains influenza strains from two influenza A subtypes and two influenza B lineages.
The current product is licensed under FDA biologics framework and is marketed in the United States by GSK. The FDA-approved indication covers active immunization for prevention of disease caused by influenza A and B viruses contained in the vaccine [1].
| Product |
Active technology |
U.S. regulatory status |
Primary market |
| FLULAVAL |
Inactivated, egg-based influenza vaccine |
Legacy trivalent product; largely superseded by quadrivalent formulations |
Historical U.S. influenza market |
| FLULAVAL QUADRIVALENT |
Inactivated, split-virion, egg-based vaccine |
FDA-licensed under BLA 125254 |
U.S. seasonal influenza market |
| Fluarix QUADRIVALENT |
Inactivated, egg-based influenza vaccine |
Separate GSK product and BLA |
U.S. and international markets |
FLULAVAL QUADRIVALENT was initially approved for broader pediatric and adult use after the quadrivalent influenza vaccine transition. The formulation and labeling are updated periodically to reflect FDA-selected seasonal strains.
What is the FDA regulatory status of FLULAVAL QUADRIVALENT?
FLULAVAL QUADRIVALENT is a licensed biologic, not an NDA-approved small-molecule drug. Its FDA regulatory pathway is a Biologics License Application, or BLA, rather than an abbreviated new drug application.
The principal regulatory characteristics are:
- FDA product: FLULAVAL QUADRIVALENT
- BLA: 125254
- Manufacturer: ID Biomedical Corporation of Quebec, a GSK company
- Dosage form: Injectable suspension
- Route: Intramuscular
- Technology: Egg-derived, inactivated, split-virion influenza vaccine
- Indication: Prevention of influenza disease caused by vaccine-matched influenza A and B strains
- Population: Individuals six months and older, subject to the current seasonal label [1]
Influenza vaccines are reviewed through a recurring seasonal process. The FDA evaluates the strain composition selected for the relevant influenza season and may approve manufacturing and labeling updates without creating a new commercial product identity.
What is the Orange Book status of FLULAVAL?
FLULAVAL QUADRIVALENT does not have the typical Orange Book patent-listing profile associated with branded small-molecule drugs.
The Orange Book primarily records patents and regulatory exclusivity for products approved under the Federal Food, Drug, and Cosmetic Act. Licensed biologics such as FLULAVAL QUADRIVALENT are generally evaluated through the biologics framework. The FDA’s Purple Book is the relevant reference for licensed biological products and biosimilar or interchangeable-product determinations [2].
As a result:
| Issue |
FLULAVAL QUADRIVALENT position |
| Orange Book listing |
No conventional Orange Book patent estate identified |
| Biologic license |
Yes, under BLA 125254 |
| Twelve-year reference-product exclusivity |
Not a practical commercial barrier for this mature seasonal vaccine |
| Biosimilar listing |
No approved U.S. biosimilar version identified |
| Annual strain updates |
Material regulatory and operational requirement |
| Core commercial moat |
Manufacturing capability, regulatory history, contracts, and supply reliability |
The absence of an Orange Book patent listing does not mean the product has no intellectual-property protection. GSK may hold process, formulation, manufacturing, analytical, packaging, or platform patents. Those rights are less likely to create a single, easily identifiable generic-entry date.
When does FLULAVAL QUADRIVALENT lose exclusivity?
FLULAVAL QUADRIVALENT does not have a single meaningful patent-expiration date that determines market entry.
The product was licensed more than a decade ago, and any original formulation or manufacturing patents would be approaching expiration or may already have expired depending on filing dates, patent-term adjustments, continuations, and jurisdiction. Commercial entry remains dependent on obtaining a separate FDA biologics license and demonstrating product quality, safety, potency, and manufacturing consistency.
The effective loss of exclusivity is therefore gradual:
- Original product and process patents mature or expire.
- Manufacturers develop alternative egg-based, cell-based, recombinant, or other influenza-vaccine platforms.
- New entrants obtain separate regulatory approval.
- Payers, public-health programs, pharmacies, and government purchasers determine product allocation.
- GSK competes on price, supply, contracting, and seasonal availability.
For FLULAVAL QUADRIVALENT, regulatory and manufacturing barriers are more important than a statutory patent cliff.
How strong is the patent estate for FLULAVAL?
The direct product patent estate appears weaker as a commercial barrier than the estates supporting complex biologics, long-acting injectables, or proprietary delivery systems.
Product and formulation protection
FLULAVAL QUADRIVALENT is an established egg-based inactivated vaccine. Potential intellectual-property categories include:
- Viral propagation and antigen-yield processes
- Inactivation and purification methods
- Split-virion production
- Stabilization and formulation techniques
- Potency and quality-control assays
- Single-dose and multidose container systems
- Manufacturing automation and fill-finish processes
- Trade secrets involving yield, consistency, and production economics
These rights are difficult for competitors to assess through ordinary Orange Book review. A competing manufacturer can avoid infringement risk by using a different strain-production method, formulation, analytical process, or manufacturing site.
Method-of-use patents
Method-of-use patent protection is limited for a seasonal prophylactic vaccine. The principal use is prevention of influenza disease in the labeled population. There is no obvious disease-specific or biomarker-defined use that would create a strong secondary-patent layer comparable with oncology or immunology medicines.
What generic or biosimilar entry risks exist?
The principal entry risk is from competing influenza vaccines rather than a conventional generic launch.
Potential competitors include:
| Competitor |
Company |
Technology or positioning |
| Fluzone and Fluzone High-Dose |
Sanofi |
Inactivated influenza vaccines, including enhanced-dose products for older adults |
| Afluria |
CSL Seqirus |
Egg-based inactivated influenza vaccine |
| Fluad |
CSL Seqirus |
Adjuvanted influenza vaccine for older adults |
| Flucelvax |
CSL Seqirus |
Cell-culture-based influenza vaccine |
| Flublok |
Sanofi |
Recombinant influenza vaccine |
| Fluarix QUADRIVALENT |
GSK |
GSK’s separate egg-based quadrivalent product |
A biosimilar-style challenge is less likely to follow the commercial pattern seen in monoclonal antibodies. Seasonal influenza vaccines change antigen composition and manufacturing parameters. A competitor normally seeks its own biologics license rather than relying on an automatic substitution pathway.
The largest competitive risks are:
- Lower-cost seasonal vaccines
- Public procurement losses
- Supply shortfalls or manufacturing delays
- Preference for cell-based or recombinant products
- Greater use of adjuvanted or high-dose vaccines in older adults
- Weak vaccination uptake in low-severity influenza seasons
- GSK portfolio cannibalization between FLULAVAL and Fluarix
What is the financial trajectory for FLULAVAL and FLULAVAL QUADRIVALENT?
GSK does not disclose revenue, gross margin, units, or operating profit for FLULAVAL QUADRIVALENT separately. Product-level financial modeling therefore requires allocation from GSK’s influenza and vaccines disclosures.
GSK’s vaccines segment has been supported by a broad portfolio that includes Shingrix, Arexvy, meningitis vaccines, pertussis vaccines, and influenza products. Influenza revenue is more volatile than sales of year-round vaccines because demand is concentrated into a narrow seasonal window.
| Financial driver |
Effect on FLULAVAL economics |
| Seasonal demand |
Produces substantial quarterly and annual volatility |
| Strain match |
Strong match can increase vaccination demand and reduce inventory risk |
| Production timing |
Delays can shift sales between reporting periods |
| Government contracts |
Provide volume but create price pressure |
| Pharmacy and retail channels |
Expand access but increase promotional competition |
| Egg supply and manufacturing yield |
Affect cost and supply reliability |
| Quadrivalent competition |
Limits pricing power |
| Enhanced-dose products |
Divert older-adult demand toward premium formulations |
GSK’s influenza business is commercially important but does not have the growth profile of Shingrix or the initial launch profile of Arexvy. Its trajectory is better characterized as a mature, recurring, seasonal franchise with variable annual demand.
The financial base is supported by repeat vaccination, public-health recommendations, pharmacy distribution, and GSK’s established manufacturing network. Growth is constrained by market maturity and competition. Price increases are difficult to sustain because influenza vaccines are purchased through government, institutional, employer, pharmacy, and health-plan channels.
Which companies are challenging FLULAVAL in the competitive market?
Sanofi and CSL Seqirus are the primary commercial competitors in the U.S. influenza-vaccine market.
Sanofi competes through scale, broad distribution, Fluzone brand recognition, and enhanced-dose products. CSL Seqirus competes through a portfolio covering standard-dose, adjuvanted, cell-based, and other influenza-vaccine technologies. These offerings give competitors access to segments where an egg-based standard-dose quadrivalent product may be less differentiated.
GSK also competes internally. Fluarix QUADRIVALENT and FLULAVAL QUADRIVALENT address overlapping clinical demand, although branding, manufacturing location, customer contracts, and geographic positioning can differ.
What licensing deals and manufacturing arrangements affect FLULAVAL?
FLULAVAL’s commercial history is linked to GSK’s acquisition of ID Biomedical, which expanded GSK’s vaccine manufacturing and influenza capabilities in Canada. GSK identifies ID Biomedical Corporation of Quebec as the manufacturer associated with FLULAVAL QUADRIVALENT [1][3].
No major current third-party licensing arrangement is disclosed as the central commercial basis for FLULAVAL QUADRIVALENT. The key strategic asset is GSK’s vertically integrated vaccine infrastructure, including antigen production, quality testing, regulatory submissions, and seasonal distribution.
Manufacturing is a material barrier to entry. A competitor must establish:
- Validated biological production
- Seasonal strain-change procedures
- Potency and sterility testing
- Consistent fill-finish capacity
- FDA inspection readiness
- Cold-chain distribution
- Reliable delivery before the influenza season
A product that receives FDA approval after the main procurement cycle may have limited commercial value in that season.
What patent litigation affects FLULAVAL?
No material public U.S. patent litigation specifically involving FLULAVAL QUADRIVALENT is identified in the FDA product materials and GSK corporate disclosures cited here. There is no established Paragraph IV litigation pathway comparable with a branded oral drug because FLULAVAL QUADRIVALENT is a BLA-licensed biologic rather than an Orange Book-listed NDA product.
Potential disputes would more likely involve:
- Manufacturing-process patents
- Trade-secret misappropriation
- Regulatory exclusivity
- Contract manufacturing
- Supply agreements
- Product liability
- Strain-production or platform technology
Those issues have a different litigation profile from generic drug patent litigation.
How does FLULAVAL compare with cell-based and recombinant influenza vaccines?
| Attribute |
FLULAVAL QUADRIVALENT |
Cell-based vaccine |
Recombinant vaccine |
| Production substrate |
Chicken eggs |
Mammalian cell culture |
Recombinant protein expression |
| Commercial maturity |
High |
Established but smaller |
Established but smaller |
| Egg-adaptation concern |
Present |
Reduced |
Avoided |
| Manufacturing complexity |
Mature and scaled |
High |
High |
| Differentiation |
Cost, scale, distribution |
Technology and antigen fidelity |
Egg-free production and rapid design |
| Main risk |
Commodity pricing and seasonal demand |
Capacity and cost |
Premium pricing and market adoption |
The market is moving toward segmentation rather than complete replacement. Egg-based vaccines remain commercially significant because of manufacturing scale and established procurement channels. Cell-based and recombinant products compete where purchasers value alternative production methods or specific clinical positioning.
What are the main generic launch scenarios?
Scenario 1: Continued mature competition
GSK retains meaningful share through supply reliability, contracting, and brand familiarity. Revenue fluctuates with vaccination rates and strain severity but remains recurring.
Scenario 2: Price-led erosion
Competing egg-based vaccines increase discounting. GSK’s unit volume remains stable while revenue and margin decline.
Scenario 3: Technology migration
Cell-based, recombinant, adjuvanted, and high-dose products capture selected segments, particularly among older adults and purchasers prioritizing non-egg or enhanced formulations.
Scenario 4: Manufacturing disruption
A production delay, egg-supply problem, or quality event shifts seasonal demand to Sanofi, CSL Seqirus, or other suppliers. Because demand is time-sensitive, lost seasonal volume may not be recoverable.
What is the geographic coverage of FLULAVAL?
FLULAVAL has its strongest commercial relevance in North America, particularly the United States and Canada. GSK’s wider influenza portfolio includes FLULAVAL and Fluarix products across multiple jurisdictions, with product names, strain compositions, labels, and regulatory approvals varying by country.
Geographic performance depends on:
- Local vaccination recommendations
- Government purchasing systems
- National reimbursement rules
- Public versus private distribution
- Seasonal timing
- Local manufacturing and import requirements
- Country-specific strain selection
A U.S. product approval does not automatically establish market access in Europe, Canada, Japan, or emerging markets.
Key Takeaways
- FLULAVAL QUADRIVALENT is an FDA-licensed, egg-based, inactivated influenza vaccine under BLA 125254.
- GSK does not report FLULAVAL revenue separately, so product-level financial performance cannot be isolated from public filings.
- The product has no conventional Orange Book patent-expiration date that creates a defined generic cliff.
- Competitive entry is more likely through separately licensed influenza vaccines than through an automatic biosimilar or generic substitution pathway.
- Sanofi and CSL Seqirus are the principal commercial threats.
- Manufacturing scale, seasonal timing, supply reliability, procurement contracts, and regulatory history are more important than a single product patent.
- Financial performance is recurring but volatile because sales are concentrated in the influenza season.
- Cell-based, recombinant, adjuvanted, and high-dose vaccines create segment-level pressure, especially in older adults.
- Publicly identified litigation and Paragraph IV risk are limited compared with branded small-molecule drugs.
- The commercial franchise is mature, with value tied to execution and supply rather than exclusivity-driven pricing.
FAQs
Is FLULAVAL QUADRIVALENT a biologic or a traditional drug?
It is a biologic vaccine licensed under the FDA’s BLA framework. It is not a conventional small-molecule drug approved through an NDA.
Does FLULAVAL QUADRIVALENT have a biosimilar competitor?
No approved U.S. biosimilar version is identified. Competing influenza vaccines generally obtain independent regulatory approval rather than enter through routine biosimilar substitution.
Does GSK disclose FLULAVAL revenue?
No. GSK reports vaccine and influenza performance at higher aggregation levels and does not separately disclose FLULAVAL QUADRIVALENT revenue or profit.
Is FLULAVAL QUADRIVALENT interchangeable with Fluzone or Afluria?
Interchangeability depends on the applicable FDA labeling, age group, presentation, clinical setting, and vaccination guidance. Brand substitution is not determined solely by the fact that products are quadrivalent influenza vaccines.
What is the main investment risk for FLULAVAL?
The main risks are seasonal demand volatility, procurement-driven price pressure, manufacturing disruption, and migration toward differentiated cell-based, recombinant, adjuvanted, or high-dose influenza vaccines.
References
-
U.S. Food and Drug Administration. (2024). FLULAVAL QUADRIVALENT [Prescribing information]. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
GSK plc. (2024). Annual report 2023. GSK.
